Dianthus Therapeutics (DNTH) News Today $35.86 -1.33 (-3.59%) As of 03:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNTH Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Goldman Sachs Group Inc. Has $1.33 Million Stake in Dianthus Therapeutics, Inc. $DNTHSeptember 21, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year High - Here's WhySeptember 18, 2025 | marketbeat.comClear Street Initiates Coverage of Dianthus Therapeutics (DNTH) with Buy RecommendationSeptember 17, 2025 | msn.comDianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $65.00September 14, 2025 | marketbeat.comWedbush Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock PriceSeptember 14, 2025 | marketbeat.comStifel Nicolaus Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock PriceSeptember 14, 2025 | americanbankingnews.comDianthus Therapeutics (NASDAQ:DNTH) CFO Sells 20,000 SharesSeptember 13, 2025 | marketbeat.comDianthus Therapeutics (DNTH) Is Up 40.2% After Positive Phase 2 Myasthenia Gravis Data and $251M Equity RaiseSeptember 13, 2025 | finance.yahoo.comAlliancebernstein L.P. Cuts Stock Position in Dianthus Therapeutics, Inc. $DNTHSeptember 13, 2025 | marketbeat.comCubist Systematic Strategies LLC Sells 32,948 Shares of Dianthus Therapeutics, Inc. $DNTHSeptember 13, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase on Analyst UpgradeSeptember 12, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) CFO Ryan Savitz Sells 20,000 SharesSeptember 12, 2025 | insidertrades.comDianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional ...September 11, 2025 | markets.businessinsider.comDianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesSeptember 11, 2025 | globenewswire.comDianthus Therapeutics (NASDAQ:DNTH) Earns "Outperform" Rating from Raymond James FinancialSeptember 11, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Expected to Rise, Guggenheim Analyst SaysSeptember 11, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $67.00 at Robert W. BairdSeptember 11, 2025 | marketbeat.comDianthus Therapeutics Raises $270M Through Stock OfferingSeptember 11, 2025 | tipranks.comOctagon Capital Advisors LP Has $42.48 Million Stock Position in Dianthus Therapeutics, Inc. $DNTHSeptember 11, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week High - Here's What HappenedSeptember 11, 2025 | marketbeat.comDianthus Therapeutics Target of Unusually Large Options Trading (NASDAQ:DNTH)September 10, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down - Here's What HappenedSeptember 10, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Given Buy Rating at HC WainwrightSeptember 10, 2025 | marketbeat.comDianthus Therapeutics prices upsized $251M securities offeringSeptember 10, 2025 | msn.comDianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public OfferingSeptember 9, 2025 | globenewswire.comDianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public OfferingSeptember 9, 2025 | markets.businessinsider.comDianthus Therapeutics, Inc. (DNTH) Phase 2 MaGic Data Investor Webcast TranscriptSeptember 9, 2025 | seekingalpha.comDianthus Therapeutics, Inc. - Discusses On Phase 2 MaGic Data Presentation Conference CallSeptember 9, 2025 | seekingalpha.comDianthus Therapeutics, Inc. (DNTH) Special Call - SlideshowSeptember 8, 2025 | seekingalpha.comDianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public OfferingSeptember 8, 2025 | globenewswire.comDianthus Therapeutics Shares Jump After Promising Phase 2 gMG Trial ResultsSeptember 8, 2025 | msn.comDianthus Therapeutics Clears Key Benchmark, Hitting 80-Plus RS RatingSeptember 8, 2025 | msn.comDianthus Therapeutics stock soars after positive Phase 2 gMG trial dataSeptember 8, 2025 | investing.comDianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class ...September 8, 2025 | markets.businessinsider.comDianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class ProfileSeptember 8, 2025 | globenewswire.comDianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia GravisSeptember 7, 2025 | globenewswire.comDianthus Therapeutics, Inc. $DNTH Stake Reduced by Ally Bridge Group NY LLCSeptember 5, 2025 | marketbeat.comVestal Point Capital LP Has $30.84 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTHSeptember 4, 2025 | marketbeat.comRA Capital Management L.P. Acquires 1,000,333 Shares of Dianthus Therapeutics, Inc. $DNTHSeptember 4, 2025 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of "Buy" by AnalystsSeptember 4, 2025 | marketbeat.comBraidwell LP Sells 831,234 Shares of Dianthus Therapeutics, Inc. $DNTHSeptember 3, 2025 | marketbeat.comNuveen LLC Invests $1.17 Million in Dianthus Therapeutics, Inc. $DNTHSeptember 3, 2025 | marketbeat.comDianthus Therapeutics, Inc. $DNTH Shares Sold by Vanguard Group Inc.September 1, 2025 | marketbeat.comWalleye Capital LLC Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTHAugust 31, 2025 | marketbeat.comWedbush Lowers Earnings Estimates for Dianthus TherapeuticsAugust 26, 2025 | marketbeat.comCandriam S.C.A. Makes New Investment in Dianthus Therapeutics, Inc. $DNTHAugust 25, 2025 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 6.7% - Here's What HappenedAugust 21, 2025 | marketbeat.comLifesci Capital Has Bearish Estimate for DNTH Q3 EarningsAugust 17, 2025 | marketbeat.comFY2025 EPS Estimates for DNTH Cut by Cantor FitzgeraldAugust 15, 2025 | marketbeat.comHC Wainwright Has Bearish Forecast for DNTH Q3 EarningsAugust 14, 2025 | marketbeat.com Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DNTH Media Mentions By Week DNTH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DNTH News Sentiment▼1.151.02▲Average Medical News Sentiment DNTH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DNTH Articles This Week▼24▲DNTH Articles Average Week Get the Latest News and Ratings for DNTH and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Dianthus Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Arcellx News Arrowhead Pharmaceuticals News Vaxcyte News ACADIA Pharmaceuticals News Protagonist Therapeutics News ADMA Biologics News Mirum Pharmaceuticals News Zai Lab News Ascentage Pharma Group International News Akero Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DNTH) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNTH Stock Alerts